Onabotulinum toxin A in the treatment of chronic migraine: patient selection and special considerations

References

• Headache Classification Committee of the International Headache Society (IHS)The International Classification of Headache Disorders, 3rd edition (beta version)Cephalalgia201333962980823771276
   PubMed Web of Science ®Google Scholar
• AdamsAMSerranoDBuseDCThe impact of chronic migraine: the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline resultsCephalalgia201535756357825304766
   PubMed Web of Science ®Google Scholar
• BigalMELiptonRBMigraine chronificationCurr Neurol Neurosci Rep201111213914821243447
   PubMed Web of Science ®Google Scholar
• SchwedtTJChronic migraineBMJ2014348g141624662044
   PubMed Web of Science ®Google Scholar
• BoyerNDallelRArtolaAMonconduitLGeneral trigeminospinal central sensitization and impaired descending pain inhibitory controls contribute to migraine progressionPain201415571196120524631586
   PubMed Web of Science ®Google Scholar
• de TommasoMValerianiMGuidoMAbnormal brain processing of cutaneous pain in patients with chronic migrainePain20031011–2253212507697
   PubMed Web of Science ®Google Scholar
• PerrottaASerraoMSandriniGSensitisation of spinal cord pain processing in medication overuse headache involves supraspinal pain controlCephalalgia201030327228419614707
   PubMed Web of Science ®Google Scholar
• CoppolaGSchoenenJCortical excitability in chronic migraineCurr Pain Headache Rep20121619310022076672
   PubMed Web of Science ®Google Scholar
• EscherCMParackaLDresslerDKolleweKBotulinum toxin in the management of chronic migraine: clinical evidence and experienceTher Adv Neurol Disord201710212713528382110
   PubMed Web of Science ®Google Scholar
• BarbantiPEgeoGPharmacological trials in migraine: it’s time to reappraise where the headache is and what the pain is likeHeadache201555343944125523108
   PubMed Web of Science ®Google Scholar
• ErbguthFJFrom poison to remedy: the chequered history of botulinum toxinJ Neural Transm (Vienna)2008115455956517458494
   PubMed Web of Science ®Google Scholar
• MatakILackovićZBotulinum toxin A, brain and painProg Neurobiol20141191203959
   Web of Science ®Google Scholar
• MartinTFStages of regulated exocytosisTrends Cell Biol19977727127617708959
   PubMed Web of Science ®Google Scholar
• BinderWJBlitzerABrinMFTreatment of hyperfunctional lines of the face with botulinum toxin ADermatol Surg19982411119812059834739
   PubMed Web of Science ®Google Scholar
• SilbersteinSDGöbelHJensenRBotulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group studyCephalalgia200626779080016776693
   PubMed Web of Science ®Google Scholar
• MathewNTFrishbergBMGawelMDimitrovaRGibsonJTurkelCBOTOX CDH Study GroupBotulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trialHeadache200545429330715836565
   PubMed Web of Science ®Google Scholar
• BlumenfeldAMBinderWSilbersteinSDBlitzerAProcedures for administering botulinum toxin type A for migraine and tension-type headacheHeadache200343888489112940810
   PubMed Web of Science ®Google Scholar
• SilbersteinSDLiptonRBChronic daily headacheCurr Opin Neurol200013327728310871251
   PubMed Web of Science ®Google Scholar
• BinderWJBrinMFBlitzerASchoenrockLDPogodaJMBotulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label studyOtolaryngol Head Neck Surg2000123666967611112955
   PubMed Web of Science ®Google Scholar
• ShuhendlerAJLeeSSiuMEfficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trialsPharmacotherapy200929778479119558252
   PubMed Web of Science ®Google Scholar
• SostakPKrausePFörderreutherSReinischVStraubeABotulinum toxin type-A therapy in cluster headache: an open studyJ Headache Pain20078423624117901920
   PubMed Web of Science ®Google Scholar
• BratbakDFNordgårdSStovnerLJPilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic cluster headacheCephalalgia201636650350926232105
   PubMed Web of Science ®Google Scholar
• MillerSCorreiaFLagrataSMatharuMSOnabotulinumtoxinA for hemicrania continua: open label experience in 9 patientsJ Headache Pain2015161925902798
   PubMed Web of Science ®Google Scholar
• VolcyMTepperSJRapoportAMSheftellFDBigalMEBotulinum toxin A for the treatment of greater occipital neuralgia and trigeminal neuralgia: a case report with pathophysiological considerationsCepha-lalgia2006263336340
   Web of Science ®Google Scholar
• KapuralLStillmanMKapuralMMcIntyrePGuirgiusMMekhailNBotulinum toxin occipital nerve block for the treatment of severe occipital neuralgia: a case seriesPain Pract20077433734017986166
   PubMedGoogle Scholar
• TaylorMSilvaSCottrellCBotulinum toxin type-A (BOTOX) in the treatment of occipital neuralgia: a pilot studyHeadache200848101476148119076646
   PubMed Web of Science ®Google Scholar
• MorraMEElgebalyAElmaraezyATherapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: a systematic review and meta-analysis of randomized controlled trialsJ Headache Pain20161716327377706
   PubMed Web of Science ®Google Scholar
• Headache Classification Subcommittee of the International Headache SocietyThe International Classification of Headache Disorders: 2nd editionCephalalgia200424Suppl 1916014979299
   PubMed Web of Science ®Google Scholar
• Headache Classification CommitteeOlesenJBousserMGDienerHCNew appendix criteria open for a broader concept of chronic migraineCephalalgia200626674274616686915
   PubMed Web of Science ®Google Scholar
• AuroraSKDodickDWTurkelCCPREEMPT 1 Chronic Migraine Study GroupOnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trialCephalalgia201030779380320647170
   PubMed Web of Science ®Google Scholar
• DienerHCDodickDWAuroraSKPREEMPT 2 Chronic Migraine Study GroupOnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trialCephalalgia201030780481420647171
   PubMed Web of Science ®Google Scholar
• AuroraSKWinnerPFreemanMCOnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical programHeadache20115191358137321883197
   PubMed Web of Science ®Google Scholar
• DienerHCDodickDWTurkelCCPooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraineEur J Neurol201421685185924628923
   PubMed Web of Science ®Google Scholar
• SilbersteinSDDodickDWAuroraSKPer cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPTJ Neurol Neurosurg Psychiatry2015869996100125500317
   PubMed Web of Science ®Google Scholar
• SilbersteinSDBlumenfeldAMCadyRKOnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baselineJ Neurol Sci20133311–2485623790235
   PubMed Web of Science ®Google Scholar
• AuroraSKDodickDWDienerHCOnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical programActa Neurol Scand20141291617024107267
   PubMed Web of Science ®Google Scholar
• LiptonRBRosenNLAilaniJDeGryseREGillardPJVaronSFOnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: pooled results from the PREEMPT randomized clinical trial programCephalalgia201636989990827288354
   PubMed Web of Science ®Google Scholar
• SantoroATanziMMiscioACopettiMLeoneMP025. Two-year follow-up with OnabotulinumtoxinA for chronic migraine: a real-life evaluation of 113 patientsJ Headache Pain201516Suppl 1A18228132206
   PubMed Web of Science ®Google Scholar
• PedrazaMIde la CruzCRuizMOnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigmSpringerplus2015417625897415
   PubMed Web of Science ®Google Scholar
• GrazziLUsaiSOnabotulinum toxin A (Botox) for chronic migraine treatment: an Italian experienceNeurol Sci201536Suppl 1333526017508
   PubMed Web of Science ®Google Scholar
• KolleweKEscherCMWulffDULong-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life settingJ Neural Transm (Vienna)2016123553354027032774
   PubMed Web of Science ®Google Scholar
• Aicua-RapunIMartínez-VelascoERojoAReal-life data in 115 chronic migraine patients treated with onabotulinumtoxin A during more than one yearJ Headache Pain201617111227957623
   PubMed Web of Science ®Google Scholar
• RussoMManzoniGCTagaAThe use of onabotulinum toxin A (Botox(®)) in the treatment of chronic migraine at the Parma Headache Centre: a prospective observational studyNeurol Sci20163771127113127048312
   PubMed Web of Science ®Google Scholar
• VikelisMArgyriouAADermitzakisEVSpingosKCMitsikostasDDOnabotulinumtoxin-A treatment in Greek patients with chronic migraineJ Headache Pain20161718427640152
   PubMed Web of Science ®Google Scholar
• KhalilMZafarHWQuarshieVAhmedFProspective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.KJ Headache Pain2014155425178393
   PubMed Web of Science ®Google Scholar
• AhmedFZafarHWButureAKhalilMDoes analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuseSpringerPlus2015458926543724
   PubMed Web of Science ®Google Scholar
• Cernuda-MorollónERamónCLarrosaDAlvarezRRiescoNPascualJLong-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year?Cephalalgia2015351086486825431141
   PubMed Web of Science ®Google Scholar
• GuerzoniSPellesiLBaraldiCPiniLAIncreased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatmentJ Headache Pain2015174827146068
   PubMed Web of Science ®Google Scholar
• NegroACurtoMLionettoLMartellettiPA two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experienceJ Headache Pain201517126792662
   PubMed Web of Science ®Google Scholar
• GrazziLOnabotulinumtoxin A for chronic migraine with medication overuse: clinical results of a long-term treatmentNeurol Sci201738Suppl 114114328527077
   PubMed Web of Science ®Google Scholar
• DienerHCDodickDWGoadsbyPJLiptonRBOlesenJSilbersteinSDChronic migraine--classification, characteristics and treatmentNat Rev Neurol20128316217122331030
   PubMed Web of Science ®Google Scholar
• MathewNTJaffriSFA double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot studyHeadache200949101466147819912346
   PubMed Web of Science ®Google Scholar
• CadyRKSchreiberCPPorterJABlumenfeldAMFarmerKUA multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraineHeadache2011511213221070228
   PubMed Web of Science ®Google Scholar
• BoudreauGPGrosbergBMMcAllisterPJLiptonRBBuseDCProphylactic onabotulinumtoxinA in patients with chronic migraine and comorbid depression: An open-label, multicenter, pilot study of efficacy, safety and effect on headache-related disability, depression, and anxietyInt J Gen Med20158798625733924
   PubMed Web of Science ®Google Scholar
• BarbantiPFabbriniGPaulettiCDefazioGCruccuGBerardelliAHeadache in cranial and cervical dystoniaNeurology20056471308130915824376
   PubMed Web of Science ®Google Scholar
• WinnerPKSadowskyCHMartinezWCZunigaJAPouletteAConcurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraineHeadache20125281219122522607530
   PubMed Web of Science ®Google Scholar
• WhitcupSMTurkelCCDeGryseREBrinMFDevelopment of onabotulinumtoxinA for chronic migraineAnn N Y Acad Sci20141329678025399521
   PubMed Web of Science ®Google Scholar
• AokiKRReview of a proposed mechanism for the antinociceptive action of botulinum toxin type ANeurotoxicology200526578579316002144
   PubMed Web of Science ®Google Scholar
• AokiKRFrancisJUpdates on the antinociceptive mechanism hypothesis of botulinum toxin AParkinsonism Relat Disord201117Suppl 1S28S3321999893
   PubMed Web of Science ®Google Scholar
• DollyJOAokiKRThe structure and mode of action of different botulinum toxinsEur J Neurol200613Suppl 41917112344
   PubMed Web of Science ®Google Scholar
• ShimizuTShibataMToriumiHReduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-ANeurobiol Dis201248336737822820141
   PubMed Web of Science ®Google Scholar
• MazzocchioRCaleoMMore than at the neuromuscular synapse: actions of botulinum neurotoxin A in the central nervous systemNeuroscientist2015211446124576870
   PubMed Web of Science ®Google Scholar
• HubbardCSBecerraLSmithJHBrain changes in responders vs. non-responders in chronic migraine: markers of disease reversalFront Hum Neurosci201610497 eCollection 201627766076
   PubMed Web of Science ®Google Scholar
• Cernuda-MorollónEMartínez-CamblorPRamónCLarrosaDSerrano-PertierraEPascualJCGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraineHeadache201454698799524673487
   PubMed Web of Science ®Google Scholar
• Cernuda-MorollónERamónCMartínez-CamblorPSerrano-PertierraELarrosaDPascualJOnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migrainePain2015156582082425735000
   PubMed Web of Science ®Google Scholar
• Cernuda-MorollónELarrosaDRamónCVegaJMartínez-CamblorPPascualJInterictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraineNeurology201381141191119623975872
   PubMed Web of Science ®Google Scholar
• BarbantiPFabbriniGPesareMVanacoreNCerboRUnilateral cranial autonomic symptoms in migraineCephalalgia200222425625912100086
   PubMed Web of Science ®Google Scholar
• BarbantiPAuriliaCDall’ArmiVEgeoGFofiLBonassiSThe phenotype of migraine with unilateral cranial autonomic symptoms documents increased peripheral and central trigeminal sensitization. A case series of 757 patientsCephalalgia201636141334134026858260
   PubMed Web of Science ®Google Scholar
• GoadsbyPJEdvinssonLEkmanRVasoactive peptide release in the extracerebral circulation of humans during migraine headacheAnn Neurol19902821831871699472
   PubMed Web of Science ®Google Scholar
• BarbantiPFabbriniGVanacoreNPesareMBuzziMGSumatriptan in migraine with unilateral cranial autonomic symptoms: an open studyHeadache200343440040312656712
   PubMed Web of Science ®Google Scholar
• BarbantiPFofiLDall’ArmiVRizatriptan in migraineurs with unilateral cranial autonomic symptoms: a double-blind trialJ Headache Pain201213540741422460943
   PubMed Web of Science ®Google Scholar
• SarchielliPPiniLAZanchinGClinical-biochemical correlates of migraine attacks in rizatriptan responders and non-respondersCephalalgia200626325726516472331
   PubMed Web of Science ®Google Scholar
• JakubowskiMMcAllisterPJBajwaZHWardTNSmithPBursteinRExploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin APain2006125328629517069972
   PubMed Web of Science ®Google Scholar
• ErossEJGladstoneJPLewisSRogersRDodickDWDuration of migraine is a predictor for response to botulinum toxin type AHeadache200545430831415836566
   PubMed Web of Science ®Google Scholar
• SandriniGPerrottaATassorelliCBotulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group studyJ Headache Pain201112442743321499747
   PubMed Web of Science ®Google Scholar
• AasethKGrandeRBLundqvistCRussellMBPericranial tenderness in chronic tension-type headache: the Akershus population-based study of chronic headacheJ Headache Pain2014155825193401
   PubMed Web of Science ®Google Scholar
• LiptonRBVaronSFGrosbergBOnabotulinumtoxinA improves quality of life and reduces impact of chronic migraineNeurology201177151465147221956721
   PubMed Web of Science ®Google Scholar
• HeppZRosenNLGillardPGVaronSFMathewNDodickDWComparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: retrospective analysis of a US-based insurance claims databaseCephalalgia201636986287426692400
   PubMed Web of Science ®Google Scholar
• ScherAIMidgetteLALiptonRBRisk factors for headache chroni-ficationHeadache2008481162518184281
   PubMed Web of Science ®Google Scholar
• ManackABuseDCSerranoDTurkelCCLiptonRBRates, predictors, and consequences of remission from chronic migraine to episodic migraineNeurology201176871171821270413
   PubMed Web of Science ®Google Scholar
• ManzoniGCBonavitaVBussoneGANIRCEF (Associazione Neurologica Italiana Ricerca Cefalee)Chronic migraine classification: current knowledge and future perspectivesJ Headache Pain201112658559222028184
   PubMed Web of Science ®Google Scholar